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Volume 58, Number 5 Abstracts 1425for logistical problems (n ¼ 11), severe hemodynamic instability after
computed tomography angiography (n ¼ 7), or refused surgery (n ¼ 5).
This left 116 patients for randomization. The primary end point rate was
42% for EVAR and 47% for OR (absolute risk reduction, 5.4%; 95% conﬁ-
dence interval [CI], 13% to 23%]. The 30-day mortality was 21% in
patients assigned to EVAR compared with 25% for OR (absolute risk reduc-
tion, 4.4%; 95% CI, 11% to 20%). The mortality was 30% (95% CI, 26%-
35%) in all surgically treated patients in the nonrandomized cohort and was
26% (95% CI, 20%-32%) in patients with unfavorable anatomy for EVAR
treated by OR at trial centers.
Comment: The 30-day mortality for open repair in this study was
<30%, considerably lower than the 48.5% postulated before the study. A
subanalysis by the authors suggests that excluding patients highly unstable
for OR was not the reason for the unanticipated low operative mortality
of OR. It appears that OR in centers of excellence may be a better operation
for RAAA now than in the past. A combination of the improved OR for
RAAA and the large percentage of patients with RAAA unsuitable for
conventional EVAR suggests the effect of EVAR on overall outcomes for
treatment of RAAA may be less, and perhaps considerably less, than previ-
ously suggested.
Long-Term Clinical Effectiveness of Supervised Exercise Therapy
Versus Endovascular Revascularization for Intermittent Claudication
from a Randomized Clinical Trial
Fakhry F, Rouwet EV, den Hoed PT, et al. Br J Surg 2013;100:1164-71.
Conclusions: Over the long-term, supervised exercise therapy
(SET)-ﬁrst or endovascular revascularization (ER) therapy-ﬁrst treatment
strategies are equally effective in improving the quality of life and func-
tional performance in patients with intermittent claudication. There are
signiﬁcantly higher numbers of total invasive interventions in the ER-ﬁrst
group. This supports a SET-ﬁrst treatment strategy for intermittent
claudication.
Summary: SET and ER both improve walking performance and
quality of life in patients with intermittent claudication (Spronk S et al, Radi-
ology 2005;235:833-42; and Watson L et al, Cochrane Database Syst Rev
2008;CD000990). The Comparing Exercise Therapy with Angioplasty for
Claudication (CETAC) Trial (Spronk S et al, Radiology 2009;250:586-95)
and a systematic review comparing ER and SET for treatment of intermit-
tent claudication concluded that SET and ER were equally effective after
12 months (Frans FA et al, Br J Surg 2012;99:16-28). The current report
represents an attempt to provide longer follow-up of the CETAC trial to
provide an estimate of long-term clinical effectiveness of a SET-ﬁrst or an
ER-ﬁrst treatment strategy for patients with intermittent claudication.
CETAC was a single-center randomized trial that compared SET vs ER
as the initial treatment for patients with intermittent claudication. A total
of 151 patients were randomly assigned to SET (n ¼ 75) or ER (n ¼
76). After a median follow-up of w7 years (range, 0.07-9.17 years), there
were 17 deaths in the SET group and 15 in the ER group. Completeness
of long-term follow-up was 71% in the SET group and 84% in the ER group
(36 patients available for review in the SET group and 47 in the ER group).
Outcome measures were functional performance (pain-free maximum
walking distance, ankle-brachial pressure index), quality of life, and the
number of secondary interventions measured at baseline and at w7 years
of follow-up. Repeated-measurement and Kaplan-Meier methods were
used for data analyses. Data were analyzed on an intention-to-treat basis.
After 7 years, functional performance (P < .001) and quality of life (P <
.005) improved after both SET and ER. The number of secondary interven-
tions was higher in the SET group (P ¼ .001). The total number of endo-
vascular and surgical interventions (primary and secondary) was signiﬁcantly
higher with the ER-ﬁrst strategy, 64 interventions in the SET group and
121 in the ER group (P < .001). There were two minor amputations in
the SET group and three major amputations in the ER group.
Comment: The study has some limitations in that not all patients were
available for long-term follow-up, and the mortality and attrition ratedecreased the power to detect small differences between the SET and ER
groups. In addition, the authors did not collect information on regular exer-
cise performed after the trial. Only endovascular and surgical procedures were
considered secondary interventions. Nevertheless, the study still strongly
argues that to minimize total procedures in patients with intermittent claudi-
cation, a SET-ﬁrst rather than ER-ﬁrst treatment strategy is preferred.
Systematic Review of Exercise Training or Percutaneous Transluminal
Angioplasty for Intermittent Claudication
Frans FA, Bipat S, Reekers JA, et al. Br J Surg 2012;99:16-28.
Conclusions: The combination of percutaneous transluminal angio-
plasty (PTA) and exercise therapy (ET) may be superior to ET or PTA alone
for treatment of intermittent claudication.
Summary: One goal in patients with intermittent claudication is to
improve their walking distance with the thought that this will subsequently
improve their quality of life. Percutaneous transluminal angioplasty (PTA),
surgery, drugs, and exercise therapy (ET) all can improve symptoms in
patients with intermittent claudication. Systematic reviews have demon-
strated superiority of supervised ET (SET) over unsupervised ET for both
increasing pain-free and maximum walking distance (Bendermacher BL et
al, Cochrane Database Syst Rev 2006;CD005263; and Wind J et al, Eur
J Vasc Endovasc Surg 2007;34:1-9). A Cochran review (Fowkes FG et al,
Cochrane Database Syst Rev 2000;CD000017) indicted that there was
greater short-term beneﬁt with PTA than with exercise in patients with
intermittent claudication but that the effect was not sustained after 1 to 2
years. A second review found medical treatment (home or SET, plus risk
factor modiﬁcation) resulted in longer walking distances than PTA at 1 to
2 years (Wilson SE, Ann Vasc Surg 2010;24:498-502). The authors noted
that since this review, six additional randomized clinical trials have
compared PTA and ET during the past 5 years. They therefore decided
to perform a systematic review to summarize the results of all randomized
clinical trials comparing PTA with ET therapy. Their goal was to obtain
the best estimate of the relative effectiveness of these two approaches.
They performed a systematic review of relevant randomized clinical trials
identiﬁed from MEDLINE, Embase, and Cochrane Library Databases.
To be included in the review, the trial had to compare PTA with ET in
patients with intermittent claudication secondary to aortoiliac or femoral
popliteal occlusive disease, or both. There were 258 initial articles identiﬁed
with 11 (reporting data on eight trials) meeting inclusion criteria. There was
one trial with isolated aortoiliac obstruction, three trials with femoropopli-
teal disease, and ﬁve with combined lesions. Two trials compared PTA with
advice for ET, 4 trials compared PTA with SET, 2 trials compared PTA plus
SET with SET alone, and 2 trials compared PTA plus SET with PTA alone.
The authors concluded that heterogeneity precluded pooling of the data
even though the end points in most trials were walking distance and quality
of life. Their analysis indicated the effectiveness of PTA and ET was equiv-
alent, although PTA plus ET provided greater improvement of walking
distance and some domains of quality of life analysis compared with PTA
alone or ET alone.
Comment: The article does indeed provide a good summary of the
most up-to-date information currently available on the effectiveness of
ET and PTA in patients treated for intermittent claudication. The data
suggest that SET and PTA can both be effective in improving walking
distance in patients with claudication. Neither therapy is perfect. ET is
noninvasive, seemingly relatively inexpensive, and with less risk compared
with PTA. However, PTA may be more universally applicable and more
quickly effective than ET. Eventual failure rates are high with PTA treat-
ment of femoral popliteal disease, but angioplasty of infrainguinal arteries
is a moving target, with improvements of percutaneous techniques, such
as drug-eluting balloons and stents, potentially shortly down the road.
Two important questions not addressed in this study include the cost effec-
tiveness of each treatment strategy and the potential for each treatment
strategy to convert patients from claudication to critical limb ischemia
with therapy failure.
